Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Virpax Pharmaceuticals, Inc. - Common Stock (NQ: VRPX )

0.1800 -0.0020 (-1.10%)
Streaming Delayed Price Updated: 11:04 AM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Virpax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Get insights into the top gainers and losers of Friday's pre-market session.
Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
Via Chartmill
US Stocks Likely To Open Higher Following A Sell-Off, 'This Choppy Start To 2025 Isn't Abnormal. Don't Panic,' Says Expert Highlighting Seasonal Weakness In The First Quarter After Elections
U.S. stock futures rose on Friday following Thursday's sell-off. Futures advanced except the small-cap gauge Russell 2000. 
Via Benzinga
These stocks are moving in today's after hours session
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Unusual volume stocks in Tuesday's session
Let's have a look at the stocks with an unusual volume in today's session. 
Via Chartmill
Wondering what's happening in today's pre-market session?
The US market session of Tuesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
What's going on in today's after hours session
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
Check out the stocks that are attracting the most attention and driving market activity.
Let's dive into the action on the US markets on Friday. Here are the most active stocks that are driving the market today. 
Via Chartmill
Unusual volume stocks in Friday's session
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. 
Via Chartmill
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate
Virpax completed a U.S. Army-backed Probudur study, showing potential for prolonged pain relief and reduced opioid use in surgical recovery. 
Via Benzinga
Friday's session: gap up and gap down stocks
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
Top movers in Friday's pre-market session
Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Airbnb Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Get insights into the top gainers and losers of Thursday's after-hours session.
The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On Offering
From Spartan Capital Securities, LLC
Via GlobeNewswire
Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From Virpax Pharmaceuticals, Inc.
Via Business Wire
Virpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded Warrants
From Virpax Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why DocuSign Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Is Virpax Pharmaceuticals Stock Gaining On Friday?
Virpax Pharmaceuticals shares are up 59.4% after announcing an extended collaboration with NCATS to advance its NES100 pain management candidate. Virpax also announced results from a minipig Dose Range... 
Via Benzinga
Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.